Scientist from Karolinska University Hospital, Sweden

Niclas Nikolai Stephanson is a seasoned clinical pharmacologist and forensic chemist based at the Karolinska University Hospital in Stockholm, Sweden. With a career spanning over three decades, he has carved out a notable reputation in the scientific community, particularly in the analysis of drugs of abuse. Holding a PhD in Medicine from the prestigious Karolinska Institutet, he combines academic rigor with practical experience. Niclas is a licensed pharmacist, senior chemist, and prolific researcher whose contributions include over 35 peer-reviewed scientific publications. His research focus lies at the intersection of pharmacology and toxicology, with a specialization in mass spectrometry and method development for detecting drugs in biological materials. He plays a pivotal role in improving clinical and forensic diagnostics through enhanced analytical techniques. Niclas’s work has contributed to better accuracy in detecting and quantifying illicit and therapeutic drugs, ultimately supporting public health and justice systems. His long-standing association with one of Europe’s most reputable hospitals is a testament to his dedication, expertise, and continuous contribution to the advancement of clinical pharmacology. Stephanson stands out not only for his technical skills but also for his impactful research that bridges laboratory science with real-world applications in healthcare and law enforcement.

Professional Profile

Education

Niclas Nikolai Stephanson received his academic training at the renowned Karolinska Institutet in Stockholm, Sweden, where he earned his PhD in Medicine in 2007. His doctoral work was rooted in the Department of Medicine and focused on the interdisciplinary field of clinical pharmacology, an area combining pharmacokinetics, pharmacodynamics, and toxicology. Prior to his doctoral studies, Niclas qualified as a licensed pharmacist, which provided him with a strong foundation in pharmaceutical sciences, drug interactions, and patient-centered pharmacotherapy. His dual academic background in pharmacy and medicine positions him at the nexus of research and clinical practice. This educational pathway has enabled him to integrate principles of chemistry, biology, and medicine in his professional work. Niclas’s academic experience at Karolinska Institutet—a globally respected institution known for its role in awarding the Nobel Prize in Physiology or Medicine—further highlights the high standards and intellectual rigor of his training. The comprehensive and multidisciplinary nature of his education has empowered him to design and conduct advanced analytical research while maintaining a deep understanding of clinical implications. Overall, his educational background has significantly influenced his ability to carry out complex method development and toxicological investigations with precision and clinical relevance.

Professional Experience

Niclas Nikolai Stephanson has been professionally affiliated with Karolinska University Hospital in Stockholm since August 1992, where he currently holds the position of Senior Chemist in the Department of Clinical Pharmacology. Over the span of more than three decades, he has contributed significantly to the hospital’s mission of delivering cutting-edge clinical diagnostics and therapeutic monitoring. As a licensed pharmacist and senior forensic chemist, Niclas has specialized in the analysis of drugs of abuse, playing a key role in the development and implementation of advanced analytical techniques for routine and investigational use. His daily responsibilities involve overseeing laboratory operations, mentoring junior staff, and collaborating with clinicians to interpret toxicological results. His long tenure reflects not only technical proficiency but also institutional trust in his expertise and leadership. Working within a hospital setting, he has consistently ensured that his research aligns with real-world clinical demands, particularly in the identification and quantification of illicit substances and medications in complex biological matrices. Stephanson’s role at Karolinska University Hospital also supports legal and forensic proceedings, as accurate drug analysis is crucial for both medical and judicial outcomes. His professional experience highlights a unique blend of scientific inquiry, clinical application, and public health impact.

Research Interests

Niclas Nikolai Stephanson’s research interests are centered on clinical pharmacology, forensic toxicology, and analytical chemistry, with a particular focus on the detection and analysis of drugs of abuse. He is especially committed to method development in toxicological screening, applying advanced techniques such as mass spectrometry to improve the precision and sensitivity of drug detection. His work often explores various biological matrices—ranging from blood and urine to less conventional materials like hair or oral fluid—to assess the presence and metabolism of illicit and therapeutic substances. Niclas’s interest in mass spectrometry enables the high-resolution identification of complex compounds, which is critical for timely and accurate diagnoses in both clinical and forensic settings. He is also interested in validating new protocols for routine use in healthcare facilities, aiming to bridge the gap between research and clinical practice. Additionally, his work contributes to public safety by improving methodologies used in legal and judicial drug testing. Through collaborations and internal projects at Karolinska University Hospital, his research continues to evolve in response to emerging substances and new analytical challenges. Overall, his interests reflect a strong alignment with societal needs in healthcare and law enforcement, emphasizing both scientific innovation and practical application.

Research Skills

Niclas Nikolai Stephanson possesses a robust set of research skills that underscore his success as a senior clinical chemist and academic contributor. One of his core strengths lies in advanced method development, particularly in the field of forensic toxicology, where he designs, tests, and refines techniques for detecting drugs of abuse in biological matrices. His proficiency in mass spectrometry—including LC-MS/MS and GC-MS systems—is central to his work, enabling precise identification and quantification of substances even in trace amounts. Niclas is also skilled in biological sample preparation, including extraction and purification techniques that are critical for ensuring reliable analytical results. He demonstrates strong data analysis and validation abilities, ensuring that his methods meet rigorous standards for reproducibility, sensitivity, and specificity. In addition, he has experience in regulatory compliance and quality assurance, ensuring that laboratory practices align with healthcare and forensic standards. His skill set extends to scientific writing and publication, as evidenced by his record of more than 35 peer-reviewed articles. These competencies, combined with his practical knowledge of clinical workflows, empower him to translate complex research into diagnostic and therapeutic tools. His research skills are not only technical but also strategic, aiming to meet real-world challenges with innovative scientific solutions.

Awards and Honors

Although specific awards or honors for Niclas Nikolai Stephanson are not explicitly listed, his sustained position at Karolinska University Hospital and the volume of his peer-reviewed publications are indicative of high professional recognition and esteem. Holding a senior chemist position at one of Europe’s leading medical institutions is a reflection of both his expertise and institutional trust in his abilities. His role in the department of Clinical Pharmacology implies consistent recognition through internal appointments, research responsibilities, and possibly departmental accolades for contributions to method development and toxicological analysis. Publishing over 35 scientific articles in peer-reviewed journals also suggests peer recognition and validation of his work within the scientific community. It is not uncommon in the medical sciences for researchers with such a track record to be involved in national and international working groups or to serve as peer reviewers or advisors in forensic and clinical pharmacology. His continued association with the Karolinska Institutet—home to Nobel-level research—implies a professional standing that exceeds routine recognition. While specific honors may not be documented publicly, his contributions and career longevity highlight a professional trajectory marked by consistent achievement and expert-level contribution to clinical science.

Conclusion

Niclas Nikolai Stephanson stands as a highly accomplished clinical pharmacologist and forensic chemist whose contributions span research, diagnostics, and public health. His work at Karolinska University Hospital since 1992, combined with a PhD from Karolinska Institutet, demonstrates a career dedicated to scientific excellence and societal impact. He has specialized in the development of analytical methods using mass spectrometry to detect drugs of abuse, contributing to over 35 peer-reviewed publications. His research not only enhances clinical decision-making but also supports forensic and legal systems by ensuring accurate and timely drug testing. While his achievements are impressive, expanding his international collaborations and diversifying his research themes could further amplify his academic influence. Nonetheless, his sustained excellence and deep specialization in clinical pharmacology make him a valuable asset to the scientific and medical community. Stephanson’s profile exemplifies the rare blend of research depth, clinical utility, and long-term dedication, positioning him as a strong candidate for prestigious honors such as the Best Researcher Award. His work bridges the gap between bench science and bedside application, marking him as a leader in toxicological innovation and a model for aspiring researchers in the field.

Publications Top Notes

Title: Application of liquid chromatography combined with high resolution mass spectrometry for urine drug testing
Authors: O.M.L. Beck (Olof M.L.), A. Rylski (Alexia), N.N. Stephanson (Nikolai N.)
Citations: 4
Title: Use of LC–HRMS in full scan-XIC mode for multi-analyte urine drug testing – a step towards a ‘black-box’ solution?
Authors: N.N. Stephanson (Nikolai N.), P. Signell (Patrick), A. Helander (Anders), O.M.L. Beck (Olof M.L.)
Year: 2017
Citations: 19

Eman Zahran | Pharmaceutical Science | Best Academic Researcher Award

Posted on 08/04/2025 by ScienceFather

Assoc. Prof. Dr. Eman Zahran | Pharmaceutical Science | Best Academic Researcher Award

Associate Professor of Pharmacognosy from Deraya university, Egypt

Dr. Eman Maher Zahran is a distinguished academic and researcher in the field of pharmacognosy, currently serving as an Associate Professor at Deraya University’s Faculty of Pharmacy. With a career rooted in natural product research, her work spans the morphological study of medicinal plants to the biological activities of phytoconstituents. A Ph.D. graduate from Minia University, she has demonstrated unwavering commitment to academic excellence, scientific innovation, and student mentorship. Her research integrates traditional knowledge with advanced technologies such as metabolomic profiling, ESI-HR-MS analysis, and molecular docking. Dr. Zahran has authored over 25 impactful peer-reviewed articles and delivered talks at key international and national pharmaceutical conferences. In addition to her scholarly contributions, she is actively involved in student-centered initiatives, scientific committees, and governmental outreach programs. Her editorial and peer-review work across several international journals further amplifies her impact within the global scientific community. A strong advocate for female leadership in science, she completed the prestigious “The Woman Leads” program at Egypt’s National Training Academy. Dr. Zahran’s blend of academic excellence, innovative research, leadership in community engagement, and dedication to advancing pharmacognosy education positions her as a leading figure in Egypt’s pharmaceutical sciences landscape.

Professional Profile

Education

Dr. Eman Maher Zahran’s educational journey is deeply rooted in Minia University, where she pursued her undergraduate, master’s, and doctoral degrees in Pharmaceutical Sciences with a specialization in Pharmacognosy. She completed her B.Sc. in Pharmaceutical Sciences in 2006 with a cumulative grade of “Very Good.” Her keen interest in medicinal plants and natural product research led her to undertake pre-master courses in 2007, which served as the foundation for her M.Sc. that spanned from 2007 to 2013. Her master’s research involved the detailed phytochemical investigation of plant constituents and their pharmacological evaluation. From 2016 to 2020, she pursued her Ph.D. at the Faculty of Pharmacy, Minia University, where she delved into advanced areas such as metabolomics, molecular docking, and structure elucidation of phytoconstituents. Her doctoral work not only reflected technical expertise but also interdisciplinary collaboration. During this academic trajectory, she also completed specialized training programs and participated in scientific workshops that refined her methodological capabilities. The strength of her education lies in its comprehensive nature, encompassing foundational knowledge, research techniques, and a critical understanding of the pharmacological potential of natural compounds, all of which have laid the groundwork for her ongoing contributions to pharmaceutical research and academia.

Professional Experience

Dr. Zahran’s professional trajectory reflects a steady and strategic ascent through the academic ranks of pharmacognosy. She began her journey as a community pharmacist, transitioning into academia in 2008 as a postgraduate researcher and then as a teaching assistant. Between 2010 and 2012, she served as a grant teaching assistant for Clinical Pharmacy students. From 2016 to 2020, she was appointed Associate Lecturer at the Faculty of Pharmacy, Minia University. In 2020, she was promoted to Assistant Professor, where she continued to lead educational initiatives, mentor students, and develop curricula. As of March 2025, she holds the rank of Associate Professor at Deraya University. Dr. Zahran has also been deeply involved in co-curricular activities, supervising multiple student-led initiatives such as “Hayah,” a student entity focused on scientific and community outreach. She has contributed to post-graduate course development and served on Deraya’s Quality Assurance and Accreditation Unit. Her participation in national-level training programs like “The Woman Leads” demonstrates her leadership and civic engagement. With over 15 years of diverse experience spanning pharmacy practice, teaching, and research, Dr. Zahran has emerged as a dynamic academic professional, recognized for her commitment to excellence, innovation, and interdisciplinary collaboration.

Research Interests

Dr. Zahran’s research interests center on pharmacognosy and natural product chemistry, with a strong emphasis on isolating, identifying, and evaluating bioactive phytoconstituents derived from medicinal plants and marine algae. Her work integrates classical botanical techniques with cutting-edge technologies like ESI-HR-MS analysis and molecular docking. A unique aspect of her research involves the application of network pharmacology to uncover the multi-target mechanisms of natural compounds, especially in treating complex disorders like ADHD and osteoarthritis. Her contributions extend to investigating the wound healing, antifungal, antiplasmodial, and anti-inflammatory properties of various natural substances. Recently, she has delved into combining natural phytochemicals with stem cell therapies to enhance regenerative medicine applications. Additionally, Dr. Zahran’s studies examine the environmental and biochemical effects of phytoconstituents using in vitro, in vivo, and in silico models. This holistic and multidisciplinary approach allows her to bridge the gap between traditional herbal medicine and contemporary pharmacological science. Her interest in neuropsychiatric disorders also reflects a forward-thinking orientation, exploring novel therapeutic avenues. Through her robust pipeline of projects and publications, she continues to identify plant-based compounds with the potential to be developed into pharmaceutical agents, contributing significantly to both academic knowledge and practical healthcare innovation.

Research Skills

Dr. Eman Maher Zahran is equipped with an extensive set of research skills that make her a leading expert in pharmacognosy and natural product research. She is proficient in the morphological and micromorphological analysis of medicinal plants and marine algae, with deep expertise in isolation and structure elucidation techniques for phytochemicals. Her methodological proficiency spans thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), and advanced mass spectrometric techniques, including ESI-HR-MS. Furthermore, she demonstrates high competence in molecular docking, network pharmacology, and in silico ADME studies, which she integrates seamlessly into phytochemical investigations. Dr. Zahran is also skilled in conducting both in vitro and in vivo biological activity assessments, exploring pharmacodynamics and pharmacokinetics of bioactive compounds. Her research frequently employs interdisciplinary approaches, such as combining plant extracts with mesenchymal stem cells in regenerative medicine models. Additionally, she is adept in scientific writing and publishing, having authored numerous high-impact papers in Scopus-indexed and Web of Science journals. Her peer-review activities and editorial board membership further reflect her critical appraisal capabilities. Collectively, her skills not only underscore her technical competence but also her innovative spirit and dedication to producing translational research that advances healthcare through natural product pharmacology.

Awards and Honors

Dr. Eman Maher Zahran has garnered significant recognition for her academic achievements, both within her institution and the broader scientific community. She was honored by Deraya University for her outstanding academic contributions from 2020 onward, a period during which she published prolifically and advanced numerous research projects. Her active role in student development and community outreach, particularly through her supervision of the “Hayah” entity and ADHD-focused conferences, highlights her multifaceted impact. In 2023, she was selected to join the second cohort of the Egyptian National Training Academy’s “The Woman Leads” program, which is designed to empower and equip promising female leaders in science and education. She serves as an editorial board member and peer reviewer for multiple prestigious journals, including the Journal of Pharmaceutical Chemistry & Chemical Science, Octahedron Drug Research, and journals by the Royal Society of Chemistry. Furthermore, her selection to the scientific committee of international congresses on nanoscience and pharmacology reflects her expertise and respected standing in the academic community. These honors not only affirm her scientific merit but also her leadership, dedication to knowledge dissemination, and her influential role in shaping the future of pharmacognosy in Egypt and beyond.

Conclusion

Dr. Eman Maher Zahran exemplifies the qualities of a dedicated academic, an innovative researcher, and an inspiring mentor. Her career is marked by a relentless pursuit of excellence, from foundational studies in pharmaceutical sciences to cutting-edge research in natural product pharmacology. Her interdisciplinary focus—combining phytochemistry, molecular modeling, and regenerative medicine—demonstrates her commitment to translating traditional medicinal knowledge into therapeutic breakthroughs. Dr. Zahran’s engagement with students, leadership in research committees, and active role in scientific communication reflect her holistic academic persona. Her prolific publication record, participation in international conferences, and collaborations underscore her relevance on both national and global levels. Equally commendable is her devotion to community-based initiatives, particularly in raising awareness and support for neuropsychiatric conditions like ADHD. Her recognition through institutional awards and national leadership programs stands as a testament to her impact. As she continues to expand her research footprint and inspire the next generation of scientists, Dr. Zahran remains a vital force in the advancement of pharmacognosy and pharmaceutical sciences. Her contributions resonate far beyond the laboratory and classroom, positioning her as a role model and a key influencer in the evolving landscape of academic research and community health promotion.

Publications Top Notes

Title: Diversity, phytochemical and medicinal potential of the genus Ocimum L. (Lamiaceae)
Authors: EM Zahran, UR Abdelmohsen, HE Khalil, SY Desoukey, MA Fouad, …
Year: 2020
Citations: 86
Title: Bioactivity potential of marine natural products from scleractinia-associated microbes and in silico anti-SARS-COV-2 evaluation
Authors: EM Zahran, A Albohy, A Khalil, AH Ibrahim, HA Ahmed, EM El-Hossary, …
Year: 2020
Citations: 41
Title: Antioxidant and wound healing potential of Vitis vinifera seeds supported by phytochemical characterization and docking studies
Authors: T Al-Warhi, EM Zahran, S Selim, MM Al-Sanea, MM Ghoneim, SA Maher, …
Year: 2022
Citations: 36
Title: Multitarget in silico studies of Ocimum menthiifolium, family Lamiaceae against SARS-CoV-2 supported by molecular dynamics simulation
Authors: A Albohy, EM Zahran, UR Abdelmohsen, MA Salem, T Al-Warhi, …
Year: 2022
Citations: 29
Title: Antiulcer potential and molecular docking of flavonoids from Ocimum forskolei Benth., family Lamiaceae
Authors: EM Zahran, UR Abdelmohsen, AS Hussein, MA Salem, HE Khalil, …
Year: 2021
Citations: 27
Title: Scabicidal potential of coconut seed extract in rabbits via downregulating inflammatory/immune cross talk: A comprehensive phytochemical/GC-MS and in silico proof
Authors: EM Zahran, NMR Abdel-Maqsoud, OY Tammam, IM Abdel-Rahman, …
Year: 2022
Citations: 23
Title: New Acaciin-loaded self-assembled nanofibers as MPro inhibitors against BCV as a surrogate model for SARS-CoV-2
Authors: SA Mohamad, EM Zahran, MR Abdel Fadeel, A Albohy, MA Safwat
Year: 2021
Citations: 23
Title: New halogenated compounds from Halimeda macroloba seaweed with potential inhibitory activity against malaria
Authors: AH Elmaidomy, EM Zahran, R Soltane, A Alasiri, H Saber, CJ Ngwa, …
Year: 2022
Citations: 22
Title: Metabolic profiling, histopathological anti-ulcer study, molecular docking and molecular dynamics of ursolic acid isolated from Ocimum forskolei Benth. (family Lamiaceae)
Authors: EM Zahran, UR Abdelmohsen, AT Ayoub, MA Salem, HE Khalil, …
Year: 2020
Citations: 21
Title: Cytotoxic and anti-diabetic potential, metabolic profiling and in silico studies of Syzygium cumini (L.) Skeels belonging to family Myrtaceae
Authors: SS Eldin Elhawary, AE Elmotayam, D Alsayed, EM Zahran, MA Fouad, …
Year: 2022
Citations: 11

Rohidas Arote | Pharmaceutical Science | Biotechnology Advancement Award

Posted on 15/03/202515/03/2025 by ScienceFather

Prof. Rohidas Arote | Pharmaceutical Science | Biotechnology Advancement Award

Dr. Rohidas B. Arote is a distinguished professor in the Center for Nano and Material Sciences at Jain University, Bangalore, India. With over two decades of experience in biotechnology, gene therapy, and drug delivery, he has made substantial contributions to biomedical research. His expertise lies in biomaterials, pharmacology, toxicology, and theranostics, particularly in cancer, immune, and regenerative therapies. Having served as a professor at Seoul National University (SNU), a globally ranked institution, he has led groundbreaking research in non-viral gene delivery systems and targeted drug delivery for cancer therapy. Dr. Arote has secured major research grants, collaborated with international institutions, and delivered invited talks at global conferences. He has received prestigious awards such as the Creative Pioneering Research Award and IAAM Scientist Medal. In addition to his academic achievements, he actively contributes to international scientific societies, reviews for high-impact journals, and organizes leading scientific conferences. With a strong track record of publications, research funding, and innovation, Dr. Arote continues to be a key figure in biomedical and pharmaceutical sciences, advancing cutting-edge solutions for healthcare and drug development.

Professional Profile

Scopus Profile

Education

Dr. Rohidas B. Arote holds a Ph.D. in Biotechnology (2009) from Seoul National University, South Korea, where he specialized in gene therapy and drug delivery systems. His doctoral research focused on developing non-viral polymeric gene carriers for targeted cancer therapy. Before pursuing his Ph.D., he earned a Master of Science (M.S.) in Pharmacognosy and Phytochemistry (2002) from the University of Mumbai, India, where he gained expertise in natural product chemistry and pharmaceutical formulations. His academic journey began with a Bachelor of Science (B.S.) in Pharmaceutical Sciences (2000) from the University of Pune, India, equipping him with a strong foundation in pharmaceutics, drug formulation, and biotechnology. Throughout his education, he has been a recipient of several prestigious fellowships, including the Brain Korea (BK21) Fellowship (2008) and the Korea Science and Engineering Fellowship (KOSEF) (2005). He was also a GATE Scholar in Pharmacy (2000), a competitive national-level qualification exam conducted by IIT Kharagpur, India. His interdisciplinary academic background, spanning biotechnology, pharmaceutical sciences, and biomedical engineering, has enabled him to develop innovative solutions in gene therapy, biomaterials, and targeted drug delivery.

Professional Experience

Dr. Rohidas B. Arote has over 20 years of academic and research experience across prestigious institutions worldwide. He is currently a Professor at the Center for Nano and Material Sciences, Jain University, Bangalore (2021-present), where he leads cutting-edge research in nanomedicine and biomaterials. Prior to this, he served at Seoul National University (SNU), South Korea, as an Associate Professor (2017-2020) and Assistant Professor (2010-2017), where he developed gene delivery technologies for cancer therapy. He also worked as a Research Associate (2009-2010) at SNU, focusing on polymeric carriers for gene therapy. In addition, he held visiting professor positions at King Abdullah University of Science and Technology (KAUST), Saudi Arabia (2019-2020), and the Indian Institute of Science (IISc), Bangalore (2019-2020), contributing to advanced biomedical research. Early in his career, he gained industry experience as a Formulation & Development Scientist at Ajanta Pharma Ltd, Mumbai (2003-2004). His diverse academic, research, and industry experience has made him a leader in drug delivery, biomaterials, and biomedical engineering.

Research Interests

Dr. Rohidas B. Arote’s research focuses on gene therapy, drug delivery, biomaterials, biomedical engineering, pharmacology, toxicology, and theranostics. He is particularly interested in developing novel non-viral gene delivery systems for targeted cancer therapy. His work involves designing biodegradable polymeric nanocarriers for effective gene transfection, with applications in cancer, immune, and regenerative therapies. He explores nanotechnology-based drug delivery to enhance the bioavailability and therapeutic efficacy of pharmaceuticals. Additionally, he investigates biocompatible materials for tissue engineering and regenerative medicine, contributing to the development of next-generation biomaterials for medical applications. His interdisciplinary research bridges biotechnology, materials science, and pharmaceutical sciences, addressing critical challenges in disease treatment and drug delivery. Through collaborations with global research institutions, he continues to push the boundaries of biomedical research by integrating nanomedicine, molecular biology, and bioengineering to develop innovative therapeutic strategies.

Research Skills

Dr. Rohidas B. Arote possesses a diverse set of advanced research skills in biomedical and pharmaceutical sciences. He is an expert in nanotechnology-based drug delivery, specializing in the synthesis and characterization of biodegradable polymers for gene therapy applications. He has expertise in molecular biology techniques, including gene cloning, siRNA delivery, and CRISPR-based genome editing. His skills extend to polymeric biomaterials design, nanoparticle synthesis, and surface modification for targeted drug delivery. He is proficient in in vitro and in vivo models for evaluating gene expression, drug efficacy, and toxicity in preclinical studies. Additionally, he has experience in high-throughput screening, bioinformatics, and computational modeling for drug formulation optimization. His research involves the development of multifunctional polymeric carriers, receptor-mediated drug targeting, and biodegradable materials for regenerative medicine. His strong analytical and problem-solving abilities have enabled him to successfully secure research funding, publish in top-tier scientific journals, and contribute to cutting-edge biomedical innovations.

Awards and Honors

Dr. Rohidas B. Arote has received numerous prestigious awards for his pioneering research in gene therapy and biomaterials. He was honored with the Creative Pioneering Research Award (2017) from Seoul National University, recognizing his innovative contributions to biomedical research. He also received the IAAM Scientist Medal (2017) from the International Association of Advanced Materials, highlighting his excellence in advanced materials and nanomedicine. Other notable accolades include the Research Excellence Award (2010) from the Research Institute for Agriculture and Life Sciences and the Young Scientist Award (2008) from the 16th POLYCHAR: World Forum on Advanced Materials. He has been a Brain Korea (BK21) Fellow (2008) and received the Korea Science and Engineering Fellowship (KOSEF) (2005). His early academic achievements include being a GATE Scholar in Pharmacy (2000), a highly competitive national-level distinction. These awards reflect his outstanding research contributions, leadership in academia, and dedication to advancing biomedical sciences.

Conclusion

Dr. Rohidas B. Arote is an exceptional researcher and academic leader with a remarkable career spanning over two decades in biotechnology, gene therapy, and drug delivery. His contributions in biomaterials, nanomedicine, and regenerative therapies have significantly advanced the field of biomedical sciences. Through his research, funding acquisitions, and scientific collaborations, he has played a crucial role in developing novel drug delivery systems for cancer therapy. His achievements in securing high-impact publications, international awards, and research grants showcase his dedication to scientific excellence. In addition to his research, he has contributed as a peer reviewer, conference organizer, and mentor, shaping the next generation of biomedical researchers. As a professor at Jain University, Bangalore, and a former faculty member at Seoul National University, he continues to lead groundbreaking research in nanomedicine. With his strong academic background, innovative research, and global scientific impact, Dr. Arote stands as a deserving candidate for prestigious research awards, making a lasting impact in healthcare and pharmaceutical sciences.

Publications Top Notes

Title: Microfluidics in Bioanalytical Chemistry
Authors: R. Nisarga, P.P. Pandit, J.N. Sangshetti, R.B. Arote
Year: Not provided
Title: Exploring Antibiofilm Potential of Some New Imidazole Analogs Against C. Albicans: Synthesis, Antifungal Activity, Molecular Docking and Molecular Dynamics Studies
Authors: S.K. Pathan, A.V. Shelar, S.U. Deshmukh, R.H. Patil, J.N. Sangshetti
Year: 2023
Citations: 1
Title: In Silico Structure-Based Drug Design Approach to Find Potential Hits in Ventilator-Associated Pneumonia Caused by Pseudomonas aeruginosa
Authors: M.G. Damale, R.B. Patil, S.A. Ansari, R.B. Arote, J.N. Sangshetti
Year: 2022
Citations: 2
Title: Efficient Gene Transfection to Lung Cancer Cells via Folate-PEI-Sorbitol Gene Transporter
Authors: K. Cho, S. Kim, H. Chun, A. Lee, R.B. Arote
Year: 2022
Citations: 6
Title: Development of Novel, Biocompatible, Polyester Amines for Microglia-Targeting Gene Delivery
Authors: B. Choi, M. Ahn, S. Hong, R.B. Arote, S.J. Lee
Year: 2021
Citations: 1
Title: Insights of Tankyrases: A Novel Target for Drug Discovery
Authors: M.G. Damale, S.K. Pathan, D.B. Shinde, R.B. Arote, J.N. Sangshetti
Year: 2020
Citations: 26
Title: Boric Acid: A Versatile Catalyst in Organic Synthesis
Authors: S.K. Pathan, P.R. Mahaparale, S.U. Deshmukh, R.B. Arote, J.N. Sangshetti
Year: Not provided
Citations: 5

Mycal Dutta | Pharmaceutical Science | Best Researcher Award

Posted on 12/03/202513/03/2025 by ScienceFather

Dr. Mycal Dutta | Pharmaceutical Science | Best Researcher Award

Associate Professor at University of Science and Technology (USTC), Bangladesh

Dr. Mycal Dutta is an accomplished Associate Professor in the Department of Pharmacy at the University of Science and Technology Chittagong (USTC), Bangladesh. With nearly fourteen years of experience in academia, research, and professional practice, he has made significant contributions to pharmaceutical sciences. Dr. Dutta earned his Ph.D. in Pharmacy from Jahangirnagar University, Dhaka, in December 2022. His expertise spans pharmaceutical technology, microbiology, and clinical pharmacy. He has published 36 research papers in national and international journals, focusing on bioactive phytochemicals, drug formulation, and pharmacological investigations. As a registered “A” Grade Pharmacist, he actively contributes to professional training and advisory committees. His research interests include the isolation of medicinal plant compounds, computational drug design, and molecular docking studies. Dr. Dutta has received several research grants, including government-funded projects on ethnomedicinal plants. Apart from his academic roles, he has been involved in organizing scientific conferences and student welfare activities. His commitment to teaching, research, and pharmaceutical advancements has made him a distinguished figure in the field.

Professional Profile

Scopus Profile

Education

Dr. Mycal Dutta has a strong academic background in pharmacy. He obtained his Ph.D. in Pharmacy from Jahangirnagar University, Dhaka, in December 2022. Prior to this, he completed his Master of Pharmacy (Thesis) degree from Southern University, Bangladesh, in 2011, achieving a CGPA of 3.6 on a 4.0 scale. He earned his Bachelor of Pharmacy (Hons.) degree from the University of Science and Technology Chittagong (USTC) in 2009, graduating with First Class honors. His foundational education includes a Higher Secondary Certificate (HSC) from Govt. Hazi Muhammad Mohsin College, Chittagong, with a GPA of 4.70 out of 5.00 in 2004, and a Secondary School Certificate (SSC) from Collegiate School, Chittagong, with a GPA of 4.38 out of 5.00 in 2002. His educational journey reflects his dedication to academic excellence and pharmaceutical sciences.

Professional Experience

Dr. Mycal Dutta has extensive teaching and research experience in the field of pharmacy. He has been serving as an Associate Professor at the University of Science and Technology Chittagong (USTC) since July 2023. Previously, he worked as an Assistant Professor at BGC Trust University Bangladesh for nearly eight years (2015–2023) and as a Lecturer at the same institution for almost five years (2011–2015). In addition to his teaching roles, he has contributed significantly to academic administration, including serving as an advisor in the Student Welfare Advisory Committee at USTC and as Chief Advisor of the Career Development and Placement Club at BGC Trust University. His professional contributions extend to chairing scientific and publication committees for national conferences and participating in examination committees. His vast experience demonstrates his dedication to pharmacy education and academic leadership.

Research Interests

Dr. Mycal Dutta’s research interests focus on pharmacological and phytochemical investigations of medicinal plants. His work involves compound isolation using techniques such as Nuclear Magnetic Resonance (NMR) and Gas Chromatography-Mass Spectrometry (GC-MS). He is particularly interested in computational drug discovery, molecular docking, Quantitative Structure-Activity Relationship (QSAR) modeling, and ADME/T property analysis of natural compounds. His research aims to bridge wet lab and dry lab approaches to develop therapeutic solutions from natural products. He also explores antimicrobial studies, aseptic techniques, bacterial staining, and in vitro and in vivo pharmacological investigations. His research contributions significantly advance the understanding of bioactive phytochemicals and their therapeutic potential.

Research Skills

Dr. Mycal Dutta possesses a diverse range of research skills, including microbiological techniques such as aseptic handling, bacterial staining, and antimicrobial sensitivity testing. He is proficient in computational drug design, protein modeling, and molecular simulations. His technical expertise extends to animal research, including transgenic and knockout mouse models. He is skilled in using various molecular modeling and Computer-Aided Drug Design (CADD) software. Additionally, he has extensive experience with statistical analysis tools such as GraphPad Prism and SPSS. His proficiency in these areas enables him to conduct high-quality research and mentor students in advanced pharmaceutical investigations.

Awards and Honors

Dr. Mycal Dutta has received several prestigious research grants and recognitions. He was awarded the R&D Grant for Science and Technology (2022–2023) from the Ministry of Science and Technology, Bangladesh, for his research on bioactive phytochemicals. Additionally, he secured a research grant from BGC Trust University Bangladesh in 2017 to support his Ph.D. research. His contributions to pharmaceutical research have been acknowledged through numerous publications in high-impact journals. He has also played a key role in organizing national conferences and scientific symposiums. His commitment to research and academia has earned him a strong reputation in the field of pharmaceutical sciences.

Conclusion

Dr. Mycal Dutta is a dedicated researcher, educator, and pharmaceutical scientist committed to advancing pharmaceutical education and research. With nearly fourteen years of experience, he has made remarkable contributions to pharmacology, phytochemistry, and drug discovery. His extensive research on medicinal plants and computational drug design has positioned him as a leading expert in the field. His passion for teaching, mentoring students, and conducting groundbreaking research continues to impact the pharmaceutical sciences significantly. Through his academic leadership, professional affiliations, and research initiatives, he remains at the forefront of pharmaceutical innovation and education.

Publications Top Notes

Yusuf, A., Shaikat, M. A., Bhuiya, M. A. M., Dutta, M., Nath, A. K., & Dash, P. R. (2023). Utilizing the Medicinal Properties of Delonix regia for Diseases and Beyond: A Review of its Phytochemistry and Pharmacology. Tropical Journal of Natural Product Research, 7(12), 5355–5365. DOI: 10.26538/tjnpr/v7i12.2
Malini, S., Raj, K., Madhumathy, S., El-Hady, K. M., Islam, S., & Dutta, M. (2022). Bioinspired Advances in Nanomaterials for Sustainable Agriculture. Journal of Nanomaterials, 2022, Article ID 8926133. DOI: 10.1155/2022/8926133
Vaidya, S., Jeengar, M., Wadaan, M. A., Mahboob, S., Kumar, P., Reece, L. M., Bathula, S. R., & Dutta, M. (2022). Design and In Vitro Evaluation of Novel Cationic Lipids for siRNA Delivery in Breast Cancer Cell Lines. Evidence-Based Complementary and Alternative Medicine, 2022, Article ID 9231641. DOI: 10.1155/2022/9231641
Jadhav, V., Bhagare, A., Wahab, S., Lokhande, D., Vaidya, C., Dhayagude, A., Khalid, M., Aher, J., Mezni, A., & Dutta, M. (2022). Green Synthesized Calcium Oxide Nanoparticles (CaO NPs) Using Leaves Aqueous Extract of Moringa oleifera and Evaluation of Their Antibacterial Activities. Journal of Nanomaterials, 2022, Article ID 9047507. DOI: 10.1155/2022/9047507
Jadhav, V., Bhagare, A., Ali, I. H., Dhayagude, A., Lokhande, D., Aher, J., Jameel, M., & Dutta, M. (2022). Role of Moringa oleifera on Green Synthesis of Metal/Metal Oxide Nanomaterials. Journal of Nanomaterials, 2022, Article ID 2147393. DOI: 10.1155/2022/2147393
Alharthy, S. A., Shams Tabrez, S., Ahmed A. Mirza, A. A., Torki A. Zughaibi, Firoz, C. K., & Dutta, M. (2022). Sugiol Suppresses the Proliferation of Human U87 Glioma Cells via Induction of Apoptosis and Cell Cycle Arrest. Evidence-Based Complementary and Alternative Medicine, 2022, Article ID 7658899. DOI: 10.1155/2022/7658899
Dutta, M., Akter, T., Nezam, M., Paul, A., & Rana, M. S. (2022). In silico Molecular Docking and ADME/T Analysis of Selected Bioactive Compounds from Leucas zeylanica against Breast Cancer. BGC Trust University Journal, 6, 51–66.
Dutta, M., Tareq, A. M., Rakib, A., Mahmud, S., Sami, S. A., Mallick, J., Islam, M. N., Majumder, M., Uddin, M. Z., Alsubaie, A., & Almalki, A. S. (2021). Phytochemicals from Leucas zeylanica Targeting Main Protease of SARS-CoV-2: Chemical Profiles, Molecular Docking, and Molecular Dynamics Simulations. Biology, 10(8), 789. DOI: 10.3390/biology10080789
Dutta, M., Nezam, M., Chowdhury, S., Rakib, A., Paul, A., Sami, S. A., Uddin, M. Z., Rana, M. S., Hossain, S., Effendi, Y., Idroes, R., Tallei, T. E., Alqahtani, A. M., & Emran, T. B. (2021). Appraisals of the Bangladeshi Medicinal Plant Calotropis gigantea Used by Folk Medicine Practitioners in the Management of COVID-19: A Biochemical and Computational Approach. Frontiers in Molecular Biosciences, 8, 625391. DOI: 10.3389/fmolb.2021.625391
Rakib, A., Paul, A., Ahmed, S., Chy, M. N. U., Baral, S. K., Majumder, M., Tareq, A. T., Amin, M. N., Shahriar, A., Uddin, M. Z., Dutta, M., Tallei, T. E., Emran, T. B., & Simal-Gandara, J. (2020). Biochemical and Computational Approach of Phytocompounds from Tinospora crispa in the Management of COVID-19: Molecules; 25(17): E3936. DOI: 10.3390/molecules25173936

Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Posted on 26/12/202426/12/2024 by ScienceFather

Prof. Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Professor at Tianjin University of Traditional Chinese Medicine, China

Professor Haiyang Yu is an accomplished researcher and academic in the field of pharmacology and traditional Chinese medicine. With a focus on the anti-tumor molecular mechanisms of natural products, he has significantly contributed to cancer research. His work delves into understanding how small molecules in traditional Chinese medicine and other natural sources can target cancerous cells. Throughout his career, Professor Yu has gained recognition for his work, publishing over 40 peer-reviewed articles, including in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology. He has also led six national research projects. His lab at Tianjin University of Traditional Chinese Medicine explores the pharmacological potential of these compounds, using network pharmacology to identify new drug targets and elucidate the molecular mechanisms behind anti-tumor effects. His research has the potential to transform cancer treatment by merging the ancient wisdom of TCM with modern scientific methods.

Professional Profile

Scopus Profile

Education

Professor Haiyang Yu holds a Ph.D. from Dong-a University, where he honed his academic foundation in pharmacology and molecular biology. After earning his doctoral degree, he pursued postdoctoral research training from 2012 to 2014, furthering his expertise in the molecular mechanisms of disease and drug discovery. This rigorous academic journey provided him with the necessary skills to embark on significant research in cancer pharmacology. His educational background underscores his commitment to advancing scientific knowledge, particularly in integrating traditional medicine with modern pharmacological practices. Professor Yu’s academic credentials have shaped him into a leader in his field, allowing him to explore novel therapeutic pathways for cancer treatment through natural products and traditional Chinese medicine.

Professional Experience

Currently serving as a professor at Tianjin University of Traditional Chinese Medicine, Professor Haiyang Yu has built a distinguished career. His position allows him to influence the next generation of researchers while continuing his own innovative work. His research is primarily concerned with the anti-tumor effects of natural products, an area in which he has published extensively. He has presided over six national projects, demonstrating his leadership capabilities and ability to secure funding for significant research initiatives. Prior to this, Professor Yu gained invaluable postdoctoral experience, expanding his research scope and applying his findings in practical settings. His experience includes collaborations with international researchers, which further enhances his ability to contribute to the global understanding of cancer pharmacology. Throughout his career, Professor Yu has successfully blended traditional Chinese medicine and contemporary research techniques, achieving breakthroughs that have had an impact on both scientific and medical communities.

Research Interests

Professor Haiyang Yu’s research primarily focuses on network pharmacology, natural products, traditional Chinese medicine (TCM), and cancer drug discovery. His interest lies in uncovering the molecular mechanisms by which natural compounds, especially those derived from TCM, exhibit anti-cancer properties. By employing advanced techniques in network pharmacology, Professor Yu investigates how these compounds interact with specific drug targets to inhibit cancer cell growth. His lab’s research aims to explore novel drug targets that could lead to more effective cancer therapies. A key part of his research involves exploring the synergy between traditional Chinese medicine and modern pharmacological methods, bridging ancient knowledge with cutting-edge technology. This interdisciplinary approach is central to his work, providing new avenues for the development of cancer treatments and potentially improving the effectiveness of existing therapies.

Research Skills

Professor Haiyang Yu’s research skills encompass a broad array of advanced techniques in pharmacology, molecular biology, and bioinformatics. His expertise in network pharmacology enables him to explore the complex interactions between small molecules and drug targets, a crucial area for drug discovery. Additionally, his proficiency in cell biology and molecular biology techniques, such as cell culture, gene expression analysis, and protein assays, allows him to delve deep into the cellular mechanisms underlying cancer progression. Professor Yu’s lab also employs cutting-edge computational tools to predict drug-target interactions and evaluate the therapeutic potential of natural compounds. Furthermore, his extensive experience with bioinformatics allows for the integration of large-scale biological data, which is essential for identifying potential therapeutic pathways and developing novel cancer drugs. His skills in both experimental and computational research make him a leading figure in his field.

Awards and Honors

Professor Haiyang Yu has received numerous accolades for his groundbreaking contributions to cancer research and traditional Chinese medicine. He has been recognized for his leadership in national research projects, successfully leading six such initiatives that have received considerable funding. His outstanding scholarly work has earned him a reputation as a leading expert in his field, culminating in invitations to present at international conferences and contribute to high-impact journals. His publication record, which includes over 40 papers in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology, underscores his standing within the scientific community. These honors not only reflect his individual achievements but also highlight his capacity to drive scientific innovation in pharmacology and oncology. Professor Yu’s ongoing contributions continue to shape the direction of research in cancer therapies and natural product pharmacology.

Conclusion

Professor Haiyang Yu is an exceptional candidate for recognition as a Best Researcher. With a solid educational background, extensive professional experience, and a significant body of research publications, he has established himself as a leader in the field of cancer research and traditional Chinese medicine. His work in identifying novel anti-tumor mechanisms through natural products and network pharmacology has the potential to revolutionize cancer therapy. His leadership in national research projects, combined with his innovative research methods, has led to significant advancements in the understanding of cancer and drug discovery. As an academic and researcher, Professor Yu continues to push the boundaries of pharmacology, integrating traditional wisdom with modern scientific methodologies. His achievements reflect both personal excellence and a broader commitment to the advancement of cancer research, making him a deserving candidate for the Best Researcher Award.

Publication Top Notes

Title: Autocrine and paracrine LIF signals to collaborate sorafenib-resistance in hepatocellular carcinoma and effects of Kanglaite Injection
Authors: Shao, Y., Pu, W., Su, R., Han, L., Yu, H.
Year: 2025
Title: Intestinal FXR deficiency induces dysregulation of xanthine oxidase and accounts for sex difference in hyperuricemia
Authors: Bao, R., Chen, B., Wang, A., Zhang, Y., Wang, T.
Year: 2025
Title: Immunometabolism in cancer: basic mechanisms and new targeting strategy
Authors: Su, R., Shao, Y., Huang, M., Yu, H., Qiu, Y.
Year: 2024
Citations: 4
Title: Arnicolide D induces endoplasmic reticulum stress-mediated oncosis via ATF4 and CHOP in hepatocellular carcinoma cells
Authors: Lin, Y.-S., Sun, Z., Shen, L.-S., Chen, S., Chen, G.-Q.
Year: 2024
Citations: 6
Title: Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma
Authors: Liu, C., Lin, X., Huang, M., Qiu, Y., Yu, H.
Year: 2024
Citations: 2
Title: Energy Landscape Reveals the Underlying Mechanism of Cancer-Adipose Conversion in Gene Network Models
Authors: Chen, Z., Lu, J., Zhao, X.-M., Yu, H., Li, C.
Year: 2024
Title: Repurposing cyclovirobuxine D as a novel inhibitor of colorectal cancer progression via modulating the CCT3/YAP axis
Authors: Liu, Y., Chen, L., Wang, J., Wang, T., Yu, H.
Year: 2024
Title: The role of NCAPH in cancer treatment
Authors: Liu, C., Han, X., Zhang, S., Pu, W., Yu, H.
Year: 2024
Title: Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway
Authors: Sheng, Y., Meng, G., Zhang, M., Wang, Y., Jiang, M.
Year: 2024
Citations: 2
Title: Natural products with anti-tumorigenesis potential targeting macrophage
Authors: Liu, H., Huang, M., Xin, D., Yu, H., Pu, W.
Year: 2024

Kifayat Ullah Shah | Pharmaceutics | Best Researcher Award

Posted on 09/09/202410/09/2024 by ScienceFather

Dr. Kifayat Ullah Shah | Pharmaceutics | Best Researcher Award

Associate Professor at Quaid-i-Azam University, Pakistan

Dr. Kifayat Ullah Shah is an accomplished academic and researcher in the field of pharmaceutical sciences, currently serving as an Associate Professor at Quaid-e-Azam University in Islamabad since September 2014. He previously held positions as an Assistant Professor at Hamdard University and a Teaching Assistant at Gomal University. Dr. Shah earned his Ph.D. in Pharmaceutics from Gomal University, where he also completed his Bachelor of Pharmacy. His research interests include the formulation and development of pharmaceuticals, controlled drug delivery, and nanotechnology applications in drug delivery. He has authored several publications with significant impact, reflecting his contributions to the field, and has supervised over 35 MPhil and five PhD students. Dr. Shah has received grants for various research projects, showcasing his commitment to advancing pharmaceutical sciences. Additionally, he is actively involved in academic administration and quality assurance within higher education.

Profile

Education

Dr. Kifayat Ullah Shah holds an impressive educational background in pharmaceutical sciences. He earned his Doctor of Philosophy (Ph.D.) in Pharmaceutics from Gomal University, Dera Ismāīl Khān, Khyber Pakhtunkhwa, Pakistan, between 2008 and 2014. Prior to that, he obtained a Bachelor of Pharmacy (B.Pharmacy) degree from the same institution, Gomal University, from 2002 to 2006. His early education includes a Pre-Medical F.Sc. from Govt. P.G. College Bannu in 2000-2001 and Matriculation in Science from Govt. High School-02 Bannu in 1998-1999. This strong academic foundation has equipped Dr. Shah with the knowledge and skills necessary to excel in both research and teaching within the field of pharmaceutical sciences.

Professional Experience

Dr. Kifayat Ullah Shah has extensive professional experience in academia and the pharmaceutical industry. He has served as an Associate Professor at Quaid-e-Azam University, Islamabad, since September 2014, where he has contributed to teaching and research in pharmaceutical sciences. Prior to this role, Dr. Shah was an Assistant Professor at Hamdard University from January to August 2014 and worked as a Teaching Assistant at Gomal University for a brief period in late 2011. His early career included experience as a Production Pharmacist at Glitz Pharmaceuticals in Islamabad, where he gained practical insights into pharmaceutical production and formulation. Dr. Shah’s diverse professional background, coupled with his research focus on drug delivery systems and nanotechnology, has positioned him as a prominent figure in his field.

Research Interest

Dr. Kifayat Ullah Shah’s research interests are centered around the formulation and development of pharmaceutical products, with a particular focus on controlled drug delivery systems. His expertise encompasses a variety of advanced techniques, including microencapsulation, nanotechnology, and thermal analysis, which he applies to improve the efficacy and safety of drug formulations. Dr. Shah has conducted significant research on targeted drug delivery mechanisms, exploring innovative methods to enhance therapeutic outcomes for various medical conditions. His work also includes the design, preparation, and evaluation of controlled release polymeric formulations, aiming to investigate drug release patterns and mechanisms. Through his research, Dr. Shah seeks to contribute to the advancement of pharmaceutical sciences and improve patient care through effective drug delivery systems.

Research Skills

Dr. Kifayat Ullah Shah possesses a robust skill set in pharmaceutical research, particularly in the formulation and development of drug delivery systems. His expertise includes advanced techniques such as microencapsulation, controlled drug delivery, and targeted drug delivery, which are essential for optimizing the therapeutic effects of pharmaceuticals. Dr. Shah is proficient in utilizing various analytical instruments, including UV/Visible spectrophotometry, differential scanning calorimetry (DSC), and thermal analysis, to evaluate and characterize pharmaceutical formulations. His research skills also extend to pre-formulation studies and the application of nanotechnology in drug delivery, enabling him to design innovative solutions for complex pharmaceutical challenges. Through his comprehensive knowledge and practical experience, Dr. Shah effectively contributes to the advancement of pharmaceutical sciences and the development of new therapeutic strategies.

Award and Recognition

Dr. Kifayat Ullah Shah has garnered several awards and recognitions throughout his career, highlighting his significant contributions to the field of pharmaceutics. He successfully obtained funding for key research projects, including a grant of 0.5 million PKR from the Higher Education Commission (HEC) of Pakistan for the fabrication, characterization, and in vitro evaluation of finasteride nanoparticles. Additionally, he received a substantial grant of 4.5 million PKR for his project on silica-based nanoparticles as hemostatic agents for controlling internal bleeding. Dr. Shah has also been recognized for his academic excellence, having supervised over 35 MPhil and five PhD students, and for his impactful research publications, which have contributed to advancements in drug delivery systems. His work has earned him respect and acknowledgment in the academic and research communities, reflecting his dedication to enhancing pharmaceutical sciences and improving patient care.

Conclusion

Dr. Kifayat Ullah Shah’s impressive academic credentials, extensive research experience, impactful publications, successful funding acquisitions, and contributions to education and administrative services strongly position him as a deserving candidate for the Research for Best Researcher Award. His ongoing commitment to advancing pharmaceutical sciences through research and mentorship further strengthens his suitability for this recognition.

Publication Top Notes

“Non-pharmacological management of hypertension: in the light of current research”
- Journal: Irish Journal of Medical Science (1971-)
- Cited by: 180
- Year: 2019
- Volume: 188
- Pages: 437-452
“From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS)”
- Journal: Expert Opinion on Drug Delivery
- Cited by: 148
- Year: 2017
- Volume: 14, Issue 11
- Pages: 1325-1340
“Proniosomes derived niosomes: recent advancements in drug delivery and targeting”
- Journal: Drug Delivery
- Cited by: 121
- Year: 2017
- Volume: 24, Issue 2
- Pages: 56-69
“A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers”
- Journal: Carbohydrate Polymers
- Cited by: 106
- Year: 2020
- Volume: 250
- Pages: 116800
“Elemental analysis of some medicinal plants used in traditional medicine by atomic absorption spectrophotometer (AAS)”
- Journal: Journal of Medicinal Plants Research
- Cited by: 93
- Year: 2010
- Volume: 4, Issue 19
- Pages: 1987-1990
“Polymeric nanogels as versatile nanoplatforms for biomedical applications”
- Journal: Journal of Nanomaterials
- Cited by: 81
- Year: 2019
- Volume: 2019, Issue 1
- Pages: 1526186
“Hemostatic strategies for uncontrolled bleeding: A comprehensive update”
- Journal: Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Cited by: 73
- Year: 2021
- Volume: 109
“Development, in-vitro and in-vivo evaluation of ezetimibe-loaded solid lipid nanoparticles and their comparison with marketed product”
- Journal: Journal of Drug Delivery Science and Technology
- Cited by: 72
- Year: 2019
- Volume: 51
- Pages: 583-590
“Prevalence of non-adherence to antihypertensive medication in Asia: a systematic review and meta-analysis”
- Journal: International Journal of Clinical Pharmacy
- Cited by: 56
- Year: 2021
- Volume: 43
- Pages: 486-501
“Co-delivery strategies to overcome multidrug resistance in ovarian cancer”
- Journal: International Journal of Pharmaceutics
- Cited by: 47
- Year: 2017
- Volume: 533, Issue 1
- Pages: 111-124
“Regulating drug release behavior and kinetics from matrix tablets based on fine particle‐sized ethyl cellulose ether derivatives: An in vitro and in vivo evaluation”
- Journal: The Scientific World Journal
- Cited by: 46
- Year: 2012
- Volume: 2012, Issue 1
- Pages: 842348

Taigang Liang | Drug Design | Best Researcher Award

Posted on 19/07/202419/07/2024 by ScienceFather

Prof. Taigang Liang | Drug Design | Best Researcher Award

Professor at School of Pharmacy/Shanxi Medical University, China.

Professional Profiles:

Education

Prof. Tai Gang Liang, a distinguished scientist at Shanxi Medical University’s School of Pharmacy, has a robust educational background in pharmaceutical sciences. He earned his Doctor of Philosophy (PhD) in 2011, Master of Science (MS) in 2003, and Bachelor of Science (BS) in 2000, all from Shanxi Medical University. His extensive expertise spans drug synthesis, drug action mechanisms, computer-aided drug design, and the industrialization of traditional Chinese medicine (TCM). Prof. Liang’s research is recognized for its contributions to both the development of novel drug compounds and innovative drug design methodologies. His academic journey reflects a deep commitment to advancing pharmaceutical sciences and addressing global health challenges through cutting-edge research.

Professional Experience

Prof. Tai Gang Liang is a distinguished scientist at the School of Pharmacy, Shanxi Medical University, with extensive expertise in drug synthesis, drug action mechanisms, and computer-aided drug design. His research also focuses on the industrialization of traditional Chinese medicine (TCM). Over his career, Prof. Liang has received several prestigious awards, including being named a Shanxi Province Outstanding Young Scholar and a member of the Shanxi Province “131 Leading Talent Engineering.” He also earned the Silver Prize at the 12th “Challenge Cup” China College Entrepreneurship Plan Competition. His work has made significant contributions to advancing pharmaceutical sciences and TCM research, reflecting his dedication to innovation and excellence in the field.

Research Interest

Prof. Tai Gang Liang’s research interests encompass a broad spectrum within pharmaceutical sciences. His primary focus includes drug synthesis and drug action mechanisms, where he aims to develop novel therapeutic agents and understand their biological effects. He is also deeply involved in computer-aided drug design, utilizing computational tools to optimize drug development processes. Additionally, Prof. Liang investigates the industrialization of traditional Chinese medicine (TCM), striving to integrate traditional practices with modern scientific techniques to enhance the efficacy and application of TCM therapies. His research aims to bridge the gap between traditional and modern medicinal approaches, advancing both fields through innovative solutions and interdisciplinary collaboration.

Award and Honors

Prof. Tai Gang Liang has received several notable awards and honors in recognition of his contributions to the field of pharmaceutical sciences. He was named a Shanxi Province Outstanding Young Scholar, highlighting his exceptional achievements and potential in his research domain. He is also a member of the Shanxi Province “131 Leading Talent Engineering”, an accolade given to influential professionals in the province. Additionally, Prof. Liang was awarded the Silver Prize at the 12th “Challenge Cup” China College Entrepreneurship Plan Competition, reflecting his innovative approach and entrepreneurial spirit in scientific endeavors. These accolades underscore his dedication and significant impact in drug development and traditional Chinese medicine. 🏆🌟

Research Skills

Prof. Tai Gang Liang excels in drug synthesis, focusing on developing novel pharmaceutical compounds. His research spans drug action mechanisms, where he explores how drugs interact with biological systems to produce therapeutic effects. Liang is skilled in computer-aided drug design, using computational tools to optimize drug candidates efficiently. He also integrates Traditional Chinese Medicine (TCM) with modern scientific methods to advance drug development and industrialization. His expertise extends to biological evaluation techniques, sustainable synthesis, and analytical methods, ensuring comprehensive assessments of drug efficacy and safety. Prof. Liang’s innovative approaches contribute significantly to enhancing drug discovery and development processes. 🧪🔬💻

Publications

Green synthesis of selenium nanoparticles with extract of hawthorn fruit induced HepG2 cells apoptosis
- Authors: D Cui, T Liang, L Sun, L Meng, C Yang, L Wang, T Liang, Q Li
- Year: 2018
- Citations: 112
Comparison of the Phenolic Content and Antioxidant Activities of Apocynum venetum L. (Luo-Bu-Ma) and Two of Its Alternative Species
- Authors: T Liang, W Yue, Q Li
- Year: 2010
- Citations: 107
Selenium nanoparticles fabricated in laminarin polysaccharides solutions exert their cytotoxicities in HepG2 cells by inhibiting autophagy and promoting apoptosis
- Authors: D Cui, J Ma, T Liang, L Sun, L Meng, T Liang, Q Li
- Year: 2019
- Citations: 93
Synthesis, characterization and antitumor properties of selenium nanoparticles coupling with ferulic acid
- Authors: D Cui, C Yan, J Miao, X Zhang, J Chen, L Sun, L Meng, T Liang, Q Li
- Year: 2018
- Citations: 78
Chemopreventive Effects of Peucedanum praeruptorum DUNN and Its Major Constituents on SGC7901 Gastric Cancer Cells
- Authors: T Liang, W Yue, Q Li
- Year: 2010
- Citations: 51
Farrerol Directly Targets GSK‐3β to Activate Nrf2‐ARE Pathway and Protect EA.hy926 Cells against Oxidative Stress‐Induced Injuries
- Authors: C Yan, X Zhang, J Miao, H Yuan, E Liu, T Liang, Q Li
- Year: 2020
- Citations: 37
Apoptosis induced by farrerol in human gastric cancer SGC-7901 cells through the mitochondrial-mediated pathway
- Authors: E Liu, T Liang, X Wang, S Ban, L Han, Q Li
- Year: 2015
- Citations: 35
Diorganotin (IV) complexes with 4-nitro-N-phthaloyl-glycine: Synthesis, characterization, antitumor activity and DNA-binding studies
- Authors: C Yan, J Zhang, T Liang, Q Li
- Year: 2015
- Citations: 35
Relaxation of rat aorta by farrerol correlates with potency to reduce intracellular calcium of VSMCs
- Authors: X Qin, X Hou, M Zhang, T Liang, J Zhi, L Han, Q Li
- Year: 2014
- Citations: 31
Sustained ERK activation-mediated proliferation inhibition of farrerol on human gastric carcinoma cell line by G0/G1-phase cell-cycle arrest
- Authors: E Liu, J Li, S Shi, X Wang, T Liang, B Wu, Q Li
- Year: 2016
- Citations: 26